JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Closed

SectorHealthcare

198.07 -0.35

Overview

Share price change

24h

Current

Min

198

Max

198.64

Key metrics

By Trading Economics

Income

1.3B

1.3B

Sales

2.1B

15B

P/E

Sector Avg

92.578

34.393

EPS

2.97

Dividend yield

3.31

Profit margin

9.66

Employees

55,000

EBITDA

-4.3B

117M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.3% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.31%

2.54%

Next Earnings

29 paź 2025

Next Dividend date

15 sie 2025

Next Ex Dividend date

14 paź 2025

Market Stats

By TradingEconomics

Market Cap

12B

348B

Previous open

198.42

Previous close

198.07

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

AbbVie Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 lip 2025, 12:46 UTC

Earnings

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30 cze 2025, 13:02 UTC

Acquisitions, Mergers, Takeovers

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 kwi 2025, 13:57 UTC

Earnings

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 kwi 2025, 12:52 UTC

Earnings

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31 lip 2025, 12:08 UTC

Earnings

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31 lip 2025, 11:46 UTC

Earnings

AbbVie Raises FY Outlook

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q Adj EPS $2.97 >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q EPS 52c >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q Rev $15.42B >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31 lip 2025, 11:44 UTC

Earnings

AbbVie 2Q Net $938M >ABBV

30 cze 2025, 12:47 UTC

Acquisitions, Mergers, Takeovers

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 cze 2025, 12:33 UTC

Acquisitions, Mergers, Takeovers

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 cze 2025, 12:33 UTC

Acquisitions, Mergers, Takeovers

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 cze 2025, 12:32 UTC

Acquisitions, Mergers, Takeovers

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 cze 2025, 12:31 UTC

Acquisitions, Mergers, Takeovers

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 maj 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 kwi 2025, 12:44 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 kwi 2025, 09:33 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 kwi 2025, 16:03 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 kwi 2025, 14:00 UTC

Top News
Earnings

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 kwi 2025, 12:24 UTC

Top News
Earnings

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 kwi 2025, 12:03 UTC

Top News
Earnings

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 kwi 2025, 11:43 UTC

Earnings

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 kwi 2025, 11:43 UTC

Earnings

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

9.3% upside

12 Months Forecast

Average 216.47 USD  9.3%

High 255 USD

Low 170 USD

Based on 17 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

11

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

180.37 / 195.54Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.